New drug IBI3032 tested for safety in small human study
NCT ID NCT07134127
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety and how the body handles a single dose of IBI3032 in 40 healthy adults. Participants were randomly assigned to receive either IBI3032 or a placebo, and some groups also looked at the effect of food on the drug. The study is complete and focused on side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI3032
- What could go wrong
- This is a very early Phase 1 study in only 40 healthy people, so it cannot show whether IBI3032 works for any disease. The main goal is safety, not effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Frist Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test